Anti-Coagulants - Lebanon

Lebanon

The Anti-Coagulants market in Lebanon is anticipated to achieve a revenue of US$7.99m in 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 6.27%, leading to a market volume of US$10.83m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$16,740.00m in 2024.
Lebanon's market for anti-coagulants is experiencing a surge in demand due to an aging population and increased awareness about cardiovascular health.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Lebanon has been growing steadily over the past few years.

Customer preferences: Customers in Lebanon have shown a preference for newer oral anti-coagulants over traditional ones. This is due to the convenience of not requiring regular blood tests and having fewer dietary restrictions. Patients also prefer drugs that have a lower risk of bleeding complications.

Trends in the market: The Anti-Coagulants market in Lebanon has been growing due to an increase in the aging population and a rise in the incidence of cardiovascular diseases. The market has also seen an increase in the use of direct oral anti-coagulants (DOACs) over vitamin K antagonists (VKAs). DOACs have been shown to be more effective and safer than VKAs. The market has also seen an increase in the use of anti-coagulants for indications beyond stroke prevention in atrial fibrillation, such as treatment of venous thromboembolism.

Local special circumstances: The healthcare system in Lebanon is fragmented, with a mix of public and private providers. This has led to disparities in access and quality of care. The country's economic crisis has also led to a shortage of medical supplies and an increase in prices of drugs. This has made it difficult for patients to access and afford anti-coagulants.

Underlying macroeconomic factors: Lebanon has been facing a severe economic crisis since 2019, with high inflation, a currency devaluation, and political instability. This has led to a decrease in healthcare spending and a shortage of medical supplies. The COVID-19 pandemic has also had an impact on the market, with a decrease in patient visits to healthcare providers and delays in elective procedures. However, the market is expected to continue to grow due to an increase in the aging population and a rise in the incidence of cardiovascular diseases.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.